Related Experiment Videos
Valproate-induced hyperammonaemia in two epileptic identical twins
Journal of Neurology
|January 1, 1985
Summary
Valproate (VPA) can cause high ammonia (NH3) levels and stupor in epileptic patients. Identical twins showed increased NH3 after VPA, suggesting a genetic predisposition to this adverse effect.
Area of Science:
- Neurology
- Clinical Pharmacology
- Genetics
Background:
- Epilepsy is a common neurological disorder.
- Valproate (VPA) is a widely used antiepileptic drug.
- Hyperammonemia, elevated blood ammonia levels, can cause neurological symptoms.
Observation:
- Two identical twins with epilepsy were studied.
- One twin experienced VPA-induced stupor with very high NH3.
- Both twins exhibited increased venous NH3 after a single VPA dose.
Findings:
- Valproate administration led to a significant rise in blood ammonia levels in both epileptic twins.
- The observed hyperammonemia suggests a potential genetic susceptibility to VPA's metabolic effects.
- This response was noted even after a single loading dose of VPA.
Implications:
- VPA treatment may require careful monitoring of ammonia levels, especially in genetically predisposed individuals.
- Understanding the genetic basis of VPA-induced hyperammonemia could lead to personalized epilepsy treatment strategies.
- This case highlights a rare but serious adverse effect of VPA, crucial for clinicians to recognize.